PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate - PubMed (original) (raw)
. 2015 Apr;67(4):795-802.
doi: 10.1016/j.eururo.2014.10.027. Epub 2014 Nov 4.
Daniel Nava Rodrigues 1, Ruth Riisnaes 1, Susana Miranda 1, Ines Figueiredo 1, Pasquale Rescigno 1, Praful Ravi 1, Carmel Pezaro 1, Aurelius Omlin 1, David Lorente 1, Zafeiris Zafeiriou 1, Joaquin Mateo 1, Amelia Altavilla 1, Spyridon Sideris 1, Diletta Bianchini 1, Emily Grist 1, Khin Thway 1, Raquel Perez Lopez 1, Nina Tunariu 1, Chris Parker 2, David Dearnaley 2, Alison Reid 1, Gerhardt Attard 1, Johann de Bono 3
Affiliations
- PMID: 25454616
- PMCID: PMC4410287
- DOI: 10.1016/j.eururo.2014.10.027
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate
Roberta Ferraldeschi et al. Eur Urol. 2015 Apr.
Abstract
Background: Loss of the tumor suppressor phosphatase and tensin homolog (PTEN) occurs frequently in prostate cancers. Preclinical evidence suggests that activation of PI3K/AKT signaling through loss of PTEN can result in resistance to hormonal treatment in prostate cancer.
Objective: To explore the antitumor activity of abiraterone acetate (abiraterone) in castration-resistant prostate cancer (CRPC) patients with and without loss of PTEN protein expression.
Design, setting, and participants: We retrospectively identified patients who had received abiraterone and had hormone-sensitive prostate cancer (HSPC) and/or CRPC tissue available for PTEN immunohistochemical analysis.
Outcome measurements and statistical analysis: The primary end point was overall survival from initiation of abiraterone treatment. Relationship with outcome was analyzed using multivariate Cox regression and log-rank analyses.
Results and limitations: A total of 144 patients were identified who had received abiraterone post-docetaxel and had available tumor tissue. Overall, loss of PTEN expression was observed in 40% of patients. Matched HSPC and CRPC tumor biopsies were available for 41 patients. PTEN status in CRPC correlated with HSPC in 86% of cases. Loss of PTEN expression was associated with shorter median overall survival (14 vs 21 mo; hazard ratio [HR]: 1.75; 95% confidence interval [CI], 1.19-2.55; p=0.004) and shorter median duration of abiraterone treatment (24 vs 28 wk; HR: 1.6; 95% CI, 1.12-2.28; p=0.009). PTEN protein loss, high lactate dehydrogenase, and the presence of visceral metastases were identified as independent prognostic factors in multivariate analysis.
Conclusions: Our results indicate that loss of PTEN expression was associated with worse survival and shorter time on abiraterone treatment. Further studies in larger and prospective cohorts are warranted.
Patient summary: PTEN is a protein often lost in prostate cancer cells. In this study we evaluated if prostate cancers that lack this protein respond differently to treatment with abiraterone acetate. We demonstrated that the survival of patients with loss of PTEN is shorter than patients with normal PTEN expression.
Keywords: Abiraterone acetate; Immunohistochemistry; PTEN; Prostate cancer.
Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Figures
Fig. 1
Cytoplasmic (right) and nuclear (left) PTEN H-score in specimens with no somatic cell deletion of PTEN by fluorescent in situ hybridization (FISH) (no deletion); heterozygous somatic PTEN loss by FISH (heterozygous loss); and homozygous (biallelic) somatic PTEN loss by FISH (homozygous loss). Staining intensity in prostate cancer cells was scored 0–3 (negative; weak; moderate; intense), and this value was multiplied by the percentage of cancer cells staining positively to generate an H-score (0–300). PTEN protein loss was defined as an H-score ≤10 (red line). FISH = fluorescent in situ hybridization.
Fig. 2
Micrographs show PTEN expression by diaminobenzidine immunohistochemistry method in six samples. (A) Column A displays three micrographs of primary prostate adenocarcinoma. (A1) Needle biopsy with moderate nuclear and cytoplasmic PTEN protein expression (×100 magnification). (A2) Prostatectomy specimen with extensive PTEN protein negative adenocarcinoma infiltration. In the upper right-hand corner, cytoplasmic PTEN protein–positive benign glands are adjacent to invasive carcinoma (×50 magnification). (A3) Prostatectomy specimen showing heterogeneous PTEN protein expression (×50 magnification). Two inserted photographs at ×200 magnification demonstrate cytoplasmic positivity (upper right: short dashes square) and negativity (bottom left: long dashes square). Nuclear staining was predominantly negative in both areas. (B) Column B shows three matched metastatic castration-resistant prostate cancer samples acquired at a later time point from the same patients as the respective diagnostic samples in column A. (B1, B2) PTEN negativity has been verified in bone marrow and liver metastases, respectively (×200 magnification). (B3) PTEN nuclear and cytoplasmic positivity is demonstrated in tumor nests of a lymph node biopsy (×200 magnification). CRPC = castration-resistant prostate cancer.
Fig. 3
Kaplan-Meier survival curves from initiation of abiraterone treatment according to PTEN expression status demonstrating a significantly shorter overall survival for patients with PTEN protein loss. CI = confidence interval; HR = hazard ratio.
Similar articles
- Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Rathkopf DE, et al. Eur Urol. 2014 Nov;66(5):815-25. doi: 10.1016/j.eururo.2014.02.056. Epub 2014 Mar 6. Eur Urol. 2014. PMID: 24647231 Free PMC article. Clinical Trial. - Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.
Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, Clayton R, Heng DY, Joshua AM, Chi KN. Azad AA, et al. Eur Urol. 2015 Mar;67(3):441-7. doi: 10.1016/j.eururo.2014.01.030. Epub 2014 Jan 31. Eur Urol. 2015. PMID: 24508071 - Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K. Chi KN, et al. Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8. Lancet Oncol. 2018. PMID: 29326030 Clinical Trial. - Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series.
Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Petrelli F, et al. Clin Genitourin Cancer. 2015 Jun;13(3):193-8. doi: 10.1016/j.clgc.2014.10.006. Epub 2014 Nov 7. Clin Genitourin Cancer. 2015. PMID: 25466676 Review. - Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
Duarte C, Jimeno A, Kessler ER. Duarte C, et al. Drugs Today (Barc). 2019 Jan;55(1):5-15. doi: 10.1358/dot.2019.55.1.2914339. Drugs Today (Barc). 2019. PMID: 30740608 Review.
Cited by
- USP11 promotes prostate cancer progression by up-regulating AR and c-Myc activity.
Pornour M, Jeon HY, Ryu H, Khadka S, Xu R, Chen H, Hussain A, Lam HM, Zhuang Z, Oo HZ, Gleave M, Dong X, Wang Q, Barbieri C, Qi J. Pornour M, et al. Proc Natl Acad Sci U S A. 2024 Jul 30;121(31):e2403331121. doi: 10.1073/pnas.2403331121. Epub 2024 Jul 25. Proc Natl Acad Sci U S A. 2024. PMID: 39052835 - Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
Nguyen CB, Reimers MA, Perera C, Abida W, Chou J, Feng FY, Antonarakis ES, McKay RR, Pachynski RK, Zhang J, Reichert ZR, Palmbos PL, Caram MEV, Vaishampayan UN, Heath EI, Hopkins AC, Cieslik MP, Wu YM, Robinson DR, Baladandayuthapani V, Chinnaiyan AM, Alva AS. Nguyen CB, et al. Clin Cancer Res. 2024 Aug 1;30(15):3200-3210. doi: 10.1158/1078-0432.CCR-24-0400. Clin Cancer Res. 2024. PMID: 38787530 Clinical Trial. - Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Rescigno P, Porta N, Finneran L, Riisnaes R, Figueiredo I, Carreira S, Flohr P, Miranda S, Bertan C, Ferreira A, Crespo M, Rodrigues DN, Gurel B, Nobes J, Crabb S, Malik Z, Ralph C, McGovern U, Hoskin P, Jones RJ, Birtle A, Gale J, Sankey P, Jain S, McLaren D, Chadwick E, Espinasse A, Hall E, de Bono J. Rescigno P, et al. Eur J Cancer. 2024 Jul;205:114103. doi: 10.1016/j.ejca.2024.114103. Epub 2024 May 8. Eur J Cancer. 2024. PMID: 38729054 Free PMC article. Clinical Trial. - Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review.
Zhang D, Weng H, Zhu Z, Gong W, Ma Y. Zhang D, et al. Front Oncol. 2024 Apr 15;14:1378993. doi: 10.3389/fonc.2024.1378993. eCollection 2024. Front Oncol. 2024. PMID: 38686197 Free PMC article. - The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care.
Sindhu KK, Dovey Z, Thompson M, Nehlsen AD, Skalina KA, Malachowska B, Hasan S, Guha C, Tang J, Salgado LR. Sindhu KK, et al. BJUI Compass. 2024 Feb 8;5(4):405-425. doi: 10.1002/bco2.323. eCollection 2024 Apr. BJUI Compass. 2024. PMID: 38633827 Free PMC article. Review.
References
- Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403. - PubMed
- Schmitz M., Grignard G., Margue C., et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer. 2007;120:1284–1292. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- G0502133/MRC_/Medical Research Council/United Kingdom
- PG12-49/PCUK_/Prostate Cancer UK/United Kingdom
- 12518/CRUK_/Cancer Research UK/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- C51/A7401/DH_/Department of Health/United Kingdom
- A13239/CRUK_/Cancer Research UK/United Kingdom
- 13239/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials